A Phase 3 interventional study of 5-Fluorouracil and Capecitabine in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 45 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.
Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 12th largest by enrollment of the 97 interventional ones that give a count, is one of 3 that started in 2003, is one of 17 in phase 3, and was the 78th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Jinbo Yue · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
RemeGen Co., Ltd. · Sites in China
Ages 18+
Hallym University Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 19 · Phase 4 2
First in 1999; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 316 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 97 interventional studies. Of the 66 that completed or were terminated, 21 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 100 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Stomach Neoplasms by Hoffmann-La Roche: none open now, 2 under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2003, is one of 7 in phase 3, and was the 23rd registered.
Hoffmann-La Roche’s Stomach Neoplasms studies by the year they started, since 2003.
3 of the studies testing capecitabine in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT06748508Fudan UniversityComparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer | 2027-07-25 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 100 studies testing capecitabine in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer. The anticipated time on study treatment is at least 6 weeks and continued up to disease progression, and the target sample size is 300 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 5-FU in combination with cisplatin upto disease progression.
Drug: 5-Fluorouracil · Drug: Cisplatin
Participants will receive capecitabine in combination with cisplatin upto disease progression.
Drug: Capecitabine · Drug: Cisplatin
Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
Time to disease progression
Time frame: Up to approximately 7.3 years
Objective tumor response rate
Time frame: Up to approximately 7.3 years
Overall survival
Time frame: Up to approximately 7.3 years
Duration of response
Time frame: Up to approximately 7.3 years
Time to response
Time frame: Up to approximately 7.3 years
Incidence of adverse events
Time frame: Up to approximately 7.3 years
The record gives a start of Apr 2003, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine